Buntanetap

Buntanetap ((+) -Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT) . Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[116839-68-0]

Product Name Alternative

(+) -Phenserine; ANVS401

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/__addition__-PHENSERINE.html

Purity

99.71

Solubility

DMSO : 230 mg/mL (ultrasonic)

Smiles

CN1[C@@](N(C)CC2)([H])[C@@]2(C)C3=C1C=CC(OC(NC4=CC=CC=C4)=O)=C3

Molecular Formula

C20H23N3O2

Molecular Weight

337.42

References & Citations

[1]Fang C, et al. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients. J Prev Alzheimers Dis. 2023;10 (1) :25-33.|[2]Chen XQ, et al. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics. 2021 Dec 7;13 (12) :2109. |[3]Brossi A , Pei XF Greig NH (1996) Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties. Australian Journal of Chemistry 49, 171-181.